Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared some papers on X:
“Weekend read Pleased to share our article in ASCO DAILY NEWS on “Strategic Actions for Earlier Recognition and Better Treatment of Rare and Ultra-Rare Cancers.”
Addressing a critical gap in oncology – patients with rare cancers deserve the same precision medicine advances as common malignancies.”
Title: Strategic Actions for Earlier Recognition and Better Treatment of Rare and Ultra-Rare Cancers
Authors: Vivek Subbiah, Razelle Kurzrock
Read The Full Article
More posts featuring Vivek Subbiah and Razelle Kurzrock on OncoDaily.